000130500 001__ 130500
000130500 005__ 20240125162931.0
000130500 0247_ $$2doi$$a10.1186/cc11150
000130500 0248_ $$2sideral$$a76589
000130500 037__ $$aART-2012-76589
000130500 041__ $$aeng
000130500 100__ $$aLorente,L.
000130500 245__ $$aSurvival and mitochondrial function in septic patients according to mitochondrial DNA haplogroup
000130500 260__ $$c2012
000130500 5060_ $$aAccess copy available to the general public$$fUnrestricted
000130500 5203_ $$aIntroduction
We recently found that platelet cytochrome c oxidase (COX) activities and quantities in 6-month-survival septic patients are significantly higher than those of patients who died before 6 months. Other studies suggested that the mitochondrial DNA (mtDNA) genotype could play a major role in sepsis survival. Given that COX catalytic subunits are encoded by mtDNA, the objective of the present study was to explore whether mtDNA population genetic variation could affect COX activity and quantity and favors sepsis survival.
Methods
A prospective, multicenter, observational study was carried out in six Spanish ICUs. We included 96 patients with severe sepsis. We determined the mtDNA haplogroup, the COX specific activity/citrate synthase specific activity (COXa/CSa) ratio and the COX quantity/citrate synthase specific activity (COXq/CSa) ratio in circulating platelets at the time of diagnosis, day 4 and day 8. We used survival at 1 and 6 months as endpoints.
Results
Patients with the JT mtDNA haplogroup (n = 15) showed higher COXq/CSa ratio at day 4 (P = 0.04) and day 8 (P = 0.02) than those with other haplogroups (n = 81). Logistic regression analysis showed that the JT mtDNA haplogroup (odds ratio = 0.18; 95% confidence interval = 0.04 to 0.94; P = 0.04) and COXq/CSa ratio (odds ratio = 0.53; 95% confidence interval = 0.30 to 0.93; P = 0.03) were associated with 1-month survival after controlling for age and lactic acid levels.
Conclusions
The novel findings of our study are that 1-month surviving septic patients showed higher COXq/CSa ratio than nonsurviving individuals, that patients from the JT mtDNA haplogroup showed a higher COXq/CSa ratio and that JT patients had a higher 1-month survival than patients from other mtDNA haplogroups.
000130500 540__ $$9info:eu-repo/semantics/openAccess$$aby$$uhttp://creativecommons.org/licenses/by/3.0/es/
000130500 590__ $$a4.718$$b2012
000130500 591__ $$aCRITICAL CARE MEDICINE$$b5 / 26 = 0.192$$c2012$$dQ1$$eT1
000130500 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000130500 700__ $$aIceta,R.
000130500 700__ $$aMartín,M. M.
000130500 700__ $$0(orcid)0000-0002-3217-1424$$aLópez-Gallardo,E.$$uUniversidad de Zaragoza
000130500 700__ $$aSolé-Violán,J.
000130500 700__ $$aBlanquer,J.
000130500 700__ $$aLabarta,L.
000130500 700__ $$aDíaz,C.
000130500 700__ $$0(orcid)0000-0003-1770-6299$$aJiménez,A.$$uUniversidad de Zaragoza
000130500 700__ $$aMontoya,J.
000130500 700__ $$0(orcid)0000-0002-0269-7337$$aRuiz-Pesini,E.$$uUniversidad de Zaragoza
000130500 7102_ $$11002$$2060$$aUniversidad de Zaragoza$$bDpto. Bioq.Biolog.Mol. Celular$$cÁrea Bioquímica y Biolog.Mole.
000130500 773__ $$g16, 1 (2012)$$pCrit. care$$tCritical care$$x1364-8535
000130500 8564_ $$s266771$$uhttps://zaguan.unizar.es/record/130500/files/texto_completo.pdf$$yVersión publicada
000130500 8564_ $$s2590393$$uhttps://zaguan.unizar.es/record/130500/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000130500 909CO $$ooai:zaguan.unizar.es:130500$$particulos$$pdriver
000130500 951__ $$a2024-01-25-15:15:45
000130500 980__ $$aARTICLE